nodes	percent_of_prediction	percent_of_DWPC	metapath
Roflumilast—Haematochezia—Capecitabine—colon cancer	0.03	0.03	CcSEcCtD
Roflumilast—Renal failure acute—Irinotecan—colon cancer	0.0142	0.0142	CcSEcCtD
Roflumilast—Gastrooesophageal reflux disease—Capecitabine—colon cancer	0.0134	0.0134	CcSEcCtD
Roflumilast—Weight decreased—Vincristine—colon cancer	0.0105	0.0105	CcSEcCtD
Roflumilast—Pneumonia—Vincristine—colon cancer	0.0104	0.0104	CcSEcCtD
Roflumilast—Depression—Vincristine—colon cancer	0.0103	0.0103	CcSEcCtD
Roflumilast—Weight decreased—Irinotecan—colon cancer	0.0102	0.0102	CcSEcCtD
Roflumilast—Pneumonia—Irinotecan—colon cancer	0.0102	0.0102	CcSEcCtD
Roflumilast—Pneumonia—Fluorouracil—colon cancer	0.00972	0.00972	CcSEcCtD
Roflumilast—Infestation—Fluorouracil—colon cancer	0.00967	0.00967	CcSEcCtD
Roflumilast—Infestation NOS—Fluorouracil—colon cancer	0.00967	0.00967	CcSEcCtD
Roflumilast—Renal failure acute—Capecitabine—colon cancer	0.00949	0.00949	CcSEcCtD
Roflumilast—Urinary tract infection—Fluorouracil—colon cancer	0.0094	0.0094	CcSEcCtD
Roflumilast—Atrial fibrillation—Capecitabine—colon cancer	0.00925	0.00925	CcSEcCtD
Roflumilast—Connective tissue disorder—Vincristine—colon cancer	0.00914	0.00914	CcSEcCtD
Roflumilast—Rhinitis—Irinotecan—colon cancer	0.00908	0.00908	CcSEcCtD
Roflumilast—Sinusitis—Fluorouracil—colon cancer	0.00907	0.00907	CcSEcCtD
Roflumilast—Connective tissue disorder—Irinotecan—colon cancer	0.0089	0.0089	CcSEcCtD
Roflumilast—Rhinitis—Fluorouracil—colon cancer	0.0087	0.0087	CcSEcCtD
Roflumilast—Cardiac disorder—Vincristine—colon cancer	0.00863	0.00863	CcSEcCtD
Roflumilast—Cardiac disorder—Irinotecan—colon cancer	0.00841	0.00841	CcSEcCtD
Roflumilast—Mediastinal disorder—Vincristine—colon cancer	0.00838	0.00838	CcSEcCtD
Roflumilast—Immune system disorder—Irinotecan—colon cancer	0.00818	0.00818	CcSEcCtD
Roflumilast—Mediastinal disorder—Irinotecan—colon cancer	0.00817	0.00817	CcSEcCtD
Roflumilast—Mental disorder—Vincristine—colon cancer	0.00815	0.00815	CcSEcCtD
Roflumilast—Gynaecomastia—Methotrexate—colon cancer	0.00804	0.00804	CcSEcCtD
Roflumilast—Back pain—Vincristine—colon cancer	0.00783	0.00783	CcSEcCtD
Roflumilast—Gastritis—Capecitabine—colon cancer	0.00776	0.00776	CcSEcCtD
Roflumilast—Back pain—Irinotecan—colon cancer	0.00763	0.00763	CcSEcCtD
Roflumilast—Muscle spasms—Irinotecan—colon cancer	0.00758	0.00758	CcSEcCtD
Roflumilast—Influenza—Capecitabine—colon cancer	0.00758	0.00758	CcSEcCtD
Roflumilast—Ill-defined disorder—Irinotecan—colon cancer	0.00732	0.00732	CcSEcCtD
Roflumilast—Vertigo—Vincristine—colon cancer	0.00728	0.00728	CcSEcCtD
Roflumilast—Malaise—Irinotecan—colon cancer	0.00711	0.00711	CcSEcCtD
Roflumilast—Vertigo—Irinotecan—colon cancer	0.00709	0.00709	CcSEcCtD
Roflumilast—Renal failure acute—Methotrexate—colon cancer	0.00707	0.00707	CcSEcCtD
Roflumilast—Myalgia—Vincristine—colon cancer	0.00689	0.00689	CcSEcCtD
Roflumilast—Weight decreased—Capecitabine—colon cancer	0.00685	0.00685	CcSEcCtD
Roflumilast—Pneumonia—Capecitabine—colon cancer	0.00679	0.00679	CcSEcCtD
Roflumilast—Infestation NOS—Capecitabine—colon cancer	0.00675	0.00675	CcSEcCtD
Roflumilast—Infestation—Capecitabine—colon cancer	0.00675	0.00675	CcSEcCtD
Roflumilast—Depression—Capecitabine—colon cancer	0.00674	0.00674	CcSEcCtD
Roflumilast—Discomfort—Irinotecan—colon cancer	0.00663	0.00663	CcSEcCtD
Roflumilast—Infection—Vincristine—colon cancer	0.00657	0.00657	CcSEcCtD
Roflumilast—Urinary tract infection—Capecitabine—colon cancer	0.00657	0.00657	CcSEcCtD
Roflumilast—Nervous system disorder—Vincristine—colon cancer	0.00648	0.00648	CcSEcCtD
Roflumilast—Myalgia—Fluorouracil—colon cancer	0.00643	0.00643	CcSEcCtD
Roflumilast—Infection—Irinotecan—colon cancer	0.00639	0.00639	CcSEcCtD
Roflumilast—Hepatobiliary disease—Capecitabine—colon cancer	0.00639	0.00639	CcSEcCtD
Roflumilast—Discomfort—Fluorouracil—colon cancer	0.00635	0.00635	CcSEcCtD
Roflumilast—Nervous system disorder—Irinotecan—colon cancer	0.00631	0.00631	CcSEcCtD
Roflumilast—Infection—Fluorouracil—colon cancer	0.00612	0.00612	CcSEcCtD
Roflumilast—Rhinitis—Capecitabine—colon cancer	0.00608	0.00608	CcSEcCtD
Roflumilast—Nervous system disorder—Fluorouracil—colon cancer	0.00605	0.00605	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Vincristine—colon cancer	0.00602	0.00602	CcSEcCtD
Roflumilast—Insomnia—Vincristine—colon cancer	0.00598	0.00598	CcSEcCtD
Roflumilast—Connective tissue disorder—Capecitabine—colon cancer	0.00596	0.00596	CcSEcCtD
Roflumilast—Insomnia—Irinotecan—colon cancer	0.00582	0.00582	CcSEcCtD
Roflumilast—Decreased appetite—Vincristine—colon cancer	0.00575	0.00575	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Vincristine—colon cancer	0.00571	0.00571	CcSEcCtD
Roflumilast—Fatigue—Vincristine—colon cancer	0.0057	0.0057	CcSEcCtD
Roflumilast—Dyspepsia—Irinotecan—colon cancer	0.00567	0.00567	CcSEcCtD
Roflumilast—Constipation—Vincristine—colon cancer	0.00565	0.00565	CcSEcCtD
Roflumilast—Cardiac disorder—Capecitabine—colon cancer	0.00563	0.00563	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.00562	0.00562	CcSEcCtD
Roflumilast—Decreased appetite—Irinotecan—colon cancer	0.0056	0.0056	CcSEcCtD
Roflumilast—Insomnia—Fluorouracil—colon cancer	0.00558	0.00558	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Irinotecan—colon cancer	0.00556	0.00556	CcSEcCtD
Roflumilast—Fatigue—Irinotecan—colon cancer	0.00555	0.00555	CcSEcCtD
Roflumilast—Constipation—Irinotecan—colon cancer	0.0055	0.0055	CcSEcCtD
Roflumilast—Immune system disorder—Capecitabine—colon cancer	0.00548	0.00548	CcSEcCtD
Roflumilast—Mediastinal disorder—Capecitabine—colon cancer	0.00546	0.00546	CcSEcCtD
Roflumilast—Dyspepsia—Fluorouracil—colon cancer	0.00543	0.00543	CcSEcCtD
Roflumilast—Gastrointestinal pain—Vincristine—colon cancer	0.0054	0.0054	CcSEcCtD
Roflumilast—Decreased appetite—Fluorouracil—colon cancer	0.00536	0.00536	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Fluorouracil—colon cancer	0.00532	0.00532	CcSEcCtD
Roflumilast—Mental disorder—Capecitabine—colon cancer	0.00531	0.00531	CcSEcCtD
Roflumilast—Feeling abnormal—Irinotecan—colon cancer	0.0053	0.0053	CcSEcCtD
Roflumilast—Malnutrition—Capecitabine—colon cancer	0.00528	0.00528	CcSEcCtD
Roflumilast—Gastrointestinal pain—Irinotecan—colon cancer	0.00526	0.00526	CcSEcCtD
Roflumilast—Abdominal pain—Vincristine—colon cancer	0.00522	0.00522	CcSEcCtD
Roflumilast—Dysgeusia—Capecitabine—colon cancer	0.00517	0.00517	CcSEcCtD
Roflumilast—Back pain—Capecitabine—colon cancer	0.00511	0.00511	CcSEcCtD
Roflumilast—Abdominal pain—Irinotecan—colon cancer	0.00509	0.00509	CcSEcCtD
Roflumilast—Feeling abnormal—Fluorouracil—colon cancer	0.00508	0.00508	CcSEcCtD
Roflumilast—Muscle spasms—Capecitabine—colon cancer	0.00508	0.00508	CcSEcCtD
Roflumilast—Pneumonia—Methotrexate—colon cancer	0.00506	0.00506	CcSEcCtD
Roflumilast—Infestation NOS—Methotrexate—colon cancer	0.00503	0.00503	CcSEcCtD
Roflumilast—Infestation—Methotrexate—colon cancer	0.00503	0.00503	CcSEcCtD
Roflumilast—Depression—Methotrexate—colon cancer	0.00501	0.00501	CcSEcCtD
Roflumilast—Tremor—Capecitabine—colon cancer	0.00495	0.00495	CcSEcCtD
Roflumilast—Ill-defined disorder—Capecitabine—colon cancer	0.0049	0.0049	CcSEcCtD
Roflumilast—Urticaria—Fluorouracil—colon cancer	0.0049	0.0049	CcSEcCtD
Roflumilast—Hypersensitivity—Vincristine—colon cancer	0.00487	0.00487	CcSEcCtD
Roflumilast—Malaise—Capecitabine—colon cancer	0.00476	0.00476	CcSEcCtD
Roflumilast—Hepatobiliary disease—Methotrexate—colon cancer	0.00476	0.00476	CcSEcCtD
Roflumilast—Vertigo—Capecitabine—colon cancer	0.00474	0.00474	CcSEcCtD
Roflumilast—Hypersensitivity—Irinotecan—colon cancer	0.00474	0.00474	CcSEcCtD
Roflumilast—Asthenia—Vincristine—colon cancer	0.00474	0.00474	CcSEcCtD
Roflumilast—Palpitations—Capecitabine—colon cancer	0.00466	0.00466	CcSEcCtD
Roflumilast—Asthenia—Irinotecan—colon cancer	0.00462	0.00462	CcSEcCtD
Roflumilast—Hypersensitivity—Fluorouracil—colon cancer	0.00454	0.00454	CcSEcCtD
Roflumilast—Diarrhoea—Vincristine—colon cancer	0.00452	0.00452	CcSEcCtD
Roflumilast—Myalgia—Capecitabine—colon cancer	0.00449	0.00449	CcSEcCtD
Roflumilast—Anxiety—Capecitabine—colon cancer	0.00448	0.00448	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.00446	0.00446	CcSEcCtD
Roflumilast—Discomfort—Capecitabine—colon cancer	0.00444	0.00444	CcSEcCtD
Roflumilast—Diarrhoea—Irinotecan—colon cancer	0.0044	0.0044	CcSEcCtD
Roflumilast—Dizziness—Vincristine—colon cancer	0.00437	0.00437	CcSEcCtD
Roflumilast—Infection—Capecitabine—colon cancer	0.00428	0.00428	CcSEcCtD
Roflumilast—Dizziness—Irinotecan—colon cancer	0.00426	0.00426	CcSEcCtD
Roflumilast—Nervous system disorder—Capecitabine—colon cancer	0.00422	0.00422	CcSEcCtD
Roflumilast—Diarrhoea—Fluorouracil—colon cancer	0.00422	0.00422	CcSEcCtD
Roflumilast—Vomiting—Vincristine—colon cancer	0.0042	0.0042	CcSEcCtD
Roflumilast—Cardiac disorder—Methotrexate—colon cancer	0.00419	0.00419	CcSEcCtD
Roflumilast—Skin disorder—Capecitabine—colon cancer	0.00418	0.00418	CcSEcCtD
Roflumilast—Rash—Vincristine—colon cancer	0.00417	0.00417	CcSEcCtD
Roflumilast—Dermatitis—Vincristine—colon cancer	0.00416	0.00416	CcSEcCtD
Roflumilast—Headache—Vincristine—colon cancer	0.00414	0.00414	CcSEcCtD
Roflumilast—Vomiting—Irinotecan—colon cancer	0.00409	0.00409	CcSEcCtD
Roflumilast—Immune system disorder—Methotrexate—colon cancer	0.00408	0.00408	CcSEcCtD
Roflumilast—Dizziness—Fluorouracil—colon cancer	0.00408	0.00408	CcSEcCtD
Roflumilast—Mediastinal disorder—Methotrexate—colon cancer	0.00407	0.00407	CcSEcCtD
Roflumilast—Rash—Irinotecan—colon cancer	0.00406	0.00406	CcSEcCtD
Roflumilast—Dermatitis—Irinotecan—colon cancer	0.00405	0.00405	CcSEcCtD
Roflumilast—Headache—Irinotecan—colon cancer	0.00403	0.00403	CcSEcCtD
Roflumilast—Mental disorder—Methotrexate—colon cancer	0.00395	0.00395	CcSEcCtD
Roflumilast—Malnutrition—Methotrexate—colon cancer	0.00393	0.00393	CcSEcCtD
Roflumilast—Nausea—Vincristine—colon cancer	0.00393	0.00393	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Capecitabine—colon cancer	0.00392	0.00392	CcSEcCtD
Roflumilast—Vomiting—Fluorouracil—colon cancer	0.00392	0.00392	CcSEcCtD
Roflumilast—Insomnia—Capecitabine—colon cancer	0.0039	0.0039	CcSEcCtD
Roflumilast—Rash—Fluorouracil—colon cancer	0.00389	0.00389	CcSEcCtD
Roflumilast—Dermatitis—Fluorouracil—colon cancer	0.00388	0.00388	CcSEcCtD
Roflumilast—Headache—Fluorouracil—colon cancer	0.00386	0.00386	CcSEcCtD
Roflumilast—Dysgeusia—Methotrexate—colon cancer	0.00385	0.00385	CcSEcCtD
Roflumilast—Nausea—Irinotecan—colon cancer	0.00382	0.00382	CcSEcCtD
Roflumilast—Back pain—Methotrexate—colon cancer	0.0038	0.0038	CcSEcCtD
Roflumilast—Dyspepsia—Capecitabine—colon cancer	0.00379	0.00379	CcSEcCtD
Roflumilast—Decreased appetite—Capecitabine—colon cancer	0.00374	0.00374	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Capecitabine—colon cancer	0.00372	0.00372	CcSEcCtD
Roflumilast—Fatigue—Capecitabine—colon cancer	0.00371	0.00371	CcSEcCtD
Roflumilast—Constipation—Capecitabine—colon cancer	0.00368	0.00368	CcSEcCtD
Roflumilast—Nausea—Fluorouracil—colon cancer	0.00366	0.00366	CcSEcCtD
Roflumilast—Ill-defined disorder—Methotrexate—colon cancer	0.00365	0.00365	CcSEcCtD
Roflumilast—Feeling abnormal—Capecitabine—colon cancer	0.00355	0.00355	CcSEcCtD
Roflumilast—Malaise—Methotrexate—colon cancer	0.00354	0.00354	CcSEcCtD
Roflumilast—Vertigo—Methotrexate—colon cancer	0.00353	0.00353	CcSEcCtD
Roflumilast—Gastrointestinal pain—Capecitabine—colon cancer	0.00352	0.00352	CcSEcCtD
Roflumilast—Urticaria—Capecitabine—colon cancer	0.00342	0.00342	CcSEcCtD
Roflumilast—Abdominal pain—Capecitabine—colon cancer	0.00341	0.00341	CcSEcCtD
Roflumilast—Myalgia—Methotrexate—colon cancer	0.00335	0.00335	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.00332	0.00332	CcSEcCtD
Roflumilast—Discomfort—Methotrexate—colon cancer	0.00331	0.00331	CcSEcCtD
Roflumilast—Infection—Methotrexate—colon cancer	0.00319	0.00319	CcSEcCtD
Roflumilast—Hypersensitivity—Capecitabine—colon cancer	0.00317	0.00317	CcSEcCtD
Roflumilast—Nervous system disorder—Methotrexate—colon cancer	0.00315	0.00315	CcSEcCtD
Roflumilast—Skin disorder—Methotrexate—colon cancer	0.00312	0.00312	CcSEcCtD
Roflumilast—Asthenia—Capecitabine—colon cancer	0.00309	0.00309	CcSEcCtD
Roflumilast—Diarrhoea—Capecitabine—colon cancer	0.00295	0.00295	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Methotrexate—colon cancer	0.00292	0.00292	CcSEcCtD
Roflumilast—Insomnia—Methotrexate—colon cancer	0.0029	0.0029	CcSEcCtD
Roflumilast—Dizziness—Capecitabine—colon cancer	0.00285	0.00285	CcSEcCtD
Roflumilast—Dyspepsia—Methotrexate—colon cancer	0.00282	0.00282	CcSEcCtD
Roflumilast—Decreased appetite—Methotrexate—colon cancer	0.00279	0.00279	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Methotrexate—colon cancer	0.00277	0.00277	CcSEcCtD
Roflumilast—Fatigue—Methotrexate—colon cancer	0.00276	0.00276	CcSEcCtD
Roflumilast—Vomiting—Capecitabine—colon cancer	0.00274	0.00274	CcSEcCtD
Roflumilast—Rash—Capecitabine—colon cancer	0.00272	0.00272	CcSEcCtD
Roflumilast—Dermatitis—Capecitabine—colon cancer	0.00271	0.00271	CcSEcCtD
Roflumilast—Headache—Capecitabine—colon cancer	0.0027	0.0027	CcSEcCtD
Roflumilast—Feeling abnormal—Methotrexate—colon cancer	0.00264	0.00264	CcSEcCtD
Roflumilast—Gastrointestinal pain—Methotrexate—colon cancer	0.00262	0.00262	CcSEcCtD
Roflumilast—Nausea—Capecitabine—colon cancer	0.00256	0.00256	CcSEcCtD
Roflumilast—Urticaria—Methotrexate—colon cancer	0.00255	0.00255	CcSEcCtD
Roflumilast—Abdominal pain—Methotrexate—colon cancer	0.00254	0.00254	CcSEcCtD
Roflumilast—Hypersensitivity—Methotrexate—colon cancer	0.00236	0.00236	CcSEcCtD
Roflumilast—Asthenia—Methotrexate—colon cancer	0.0023	0.0023	CcSEcCtD
Roflumilast—Diarrhoea—Methotrexate—colon cancer	0.00219	0.00219	CcSEcCtD
Roflumilast—Dizziness—Methotrexate—colon cancer	0.00212	0.00212	CcSEcCtD
Roflumilast—Vomiting—Methotrexate—colon cancer	0.00204	0.00204	CcSEcCtD
Roflumilast—Rash—Methotrexate—colon cancer	0.00202	0.00202	CcSEcCtD
Roflumilast—Dermatitis—Methotrexate—colon cancer	0.00202	0.00202	CcSEcCtD
Roflumilast—Headache—Methotrexate—colon cancer	0.00201	0.00201	CcSEcCtD
Roflumilast—Nausea—Methotrexate—colon cancer	0.0019	0.0019	CcSEcCtD
